US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...
It stimulates specific acetylcholine receptors (called muscarinic receptors) in the brain while limiting stimulation of these ...
It stimulates specific acetylcholine receptors (called muscarinic receptors) in the brain while limiting stimulation of these receptors in the peripheral nervous system (for example, in the ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Intriguingly, the researchers also found that these receptors are more abundant in the hearts of patients with heart failure, suggesting a possible link to disease. Further investigation revealed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback